• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 3 filed by new insider Liu Pijun (Pjl)

    4/8/26 7:33:35 AM ET
    $PASW
    Apparel
    Consumer Discretionary
    Get the next $PASW alert in real time by email
    SEC FORM 3SEC Form 3
    FORM 3UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number:3235-0104
    Estimated average burden
    hours per response:0.5
    1. Name and Address of Reporting Person*
    Liu Pijun (PJL)

    (Last)(First)(Middle)
    ROOM 602, UNIT 3, BUILDING 19, PHASE 2,
    CHAOBAI RENJIA, XINGGONG WEST STREET

    (Street)
    SANHE CITY, HEBEI PROVINCE065200

    (City)(State)(Zip)

    CHINA

    (Country)
    2. Date of Event Requiring Statement (Month/Day/Year)
    10/14/2025
    3. Issuer Name and Ticker or Trading Symbol
    Ping An Biomedical Co., Ltd. [ PASW ]
    3a. Foreign Trading Symbol
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    XDirector10% Owner
    XOfficer (give title below)Other (specify below)
    CEO
    6. Individual or Joint/Group Filing (Check Applicable Line)
    XForm filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Class A Ordinary Shares12,250,000IOwner of INSPIRETECH LTD
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year)3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date ExercisableExpiration DateTitleAmount or Number of Shares
    Explanation of Responses:
    /s/ Pijun Liu04/08/2026
    ** Signature of Reporting PersonDate
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    * Form 3: SEC 1473 (03-26)
    Get the next $PASW alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PASW

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $PASW
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Liu Pijun (Pjl)

    3 - Ping An Biomedical Co., Ltd. (0001897532) (Issuer)

    4/8/26 7:33:35 AM ET
    $PASW
    Apparel
    Consumer Discretionary

    SEC Form 3 filed by new insider Liu Xianzhi (Xzl)

    3 - Ping An Biomedical Co., Ltd. (0001897532) (Issuer)

    4/1/26 6:05:50 AM ET
    $PASW
    Apparel
    Consumer Discretionary

    SEC Form 3 filed by new insider Yang Hongli (Hly)

    3 - Ping An Biomedical Co., Ltd. (0001897532) (Issuer)

    4/1/26 6:04:14 AM ET
    $PASW
    Apparel
    Consumer Discretionary

    $PASW
    SEC Filings

    View All

    SEC Form 6-K filed by Ping An Biomedical Co. Ltd.

    6-K - Ping An Biomedical Co., Ltd. (0001897532) (Filer)

    3/19/26 10:49:53 AM ET
    $PASW
    Apparel
    Consumer Discretionary

    SEC Form 6-K filed by Ping An Biomedical Co. Ltd.

    6-K - Ping An Biomedical Co., Ltd. (0001897532) (Filer)

    3/9/26 12:01:13 PM ET
    $PASW
    Apparel
    Consumer Discretionary

    SEC Form EFFECT filed by Ping An Biomedical Co. Ltd.

    EFFECT - Ping An Biomedical Co., Ltd. (0001897532) (Filer)

    2/27/26 12:15:17 AM ET
    $PASW
    Apparel
    Consumer Discretionary

    $PASW
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    All Resolutions Passed at Ping An Biomedical AGM, Clearing Path for Restructured Share Capital

    HONG KONG, March 19, 2026 (GLOBE NEWSWIRE) -- Ping An Biomedical Co., Ltd (NASDAQ:PASW) (hereinafter referred to as "Ping An Bio") announced that shareholders have approved all five resolutions at the company's 2026 Annual General Meeting, providing full authorization for an overhaul of its share capital structure, the introduction of high‑vote Class B shares, a targeted share exchange with a major shareholder, and a large‑scale share consolidation. Authorised Share Capital Changes Shareholders resolved by an ordinary resolution that, the Company authorised share capital of the Company be amended in the manner and sequence set out below with immediate effect (collectively, the Authorise

    3/19/26 10:00:00 AM ET
    $PASW
    Apparel
    Consumer Discretionary

    Ping An Biomedical Co., Ltd Announces Strategic Investment in Future Biotechnology Group to Advance Collaborative Development of the Biopharmaceutical Industry

    HONG KONG, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Ping An Biomedical Co., Ltd (NASDAQ:PASW) (hereinafter referred to as "Ping An Bio") announced that it has entered into a non-binding memorandum (the "Investment Memorandum") with Future Biotechnology Group Co., Ltd (hereinafter referred to as "Future Biotechnology Group"). The Investment Memorandum outlines an initial investment of US$30 million to be paid in cash, as well as subsequent acquisitions with a consideration, in aggregate, of US$60 million to be settled in cash and share issuances (the "Consideration Shares"). The Consideration Shares are to be held escrow and released in accordance with performance targets over an evaluation perio

    1/9/26 9:25:00 AM ET
    $PASW
    Apparel
    Consumer Discretionary

    Ping An Biomedical Co., Ltd. Receives Strategic Investment from Leading Industry Capital, Accelerating Growth in Biopharmaceutical Innovation

    HONG KONG, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Ping An Biomedical Co., Ltd. (NASDAQ:PASW) (hereinafter referred to as "Ping An Bio") today announced that it has entered into a series of share purchase agreements with several investors. Ping An Biomedical Co., Ltd. has entered into a series of share purchase agreements from several investors: Yao Jinbo, Chairman and CEO of 58 Group Inc.; Wang Donghui, Founder and Managing Partner of Amiba Capital Co., Ltd; and Li Daxue, Chairman and CEO of Magcloud Group Co., Ltd and former Senior Vice President of JD.com and its Lifetime Honorary Advisor. This round of investment further strengthens the company's long-term development in biopharmaceutical R

    1/9/26 7:05:00 AM ET
    $PASW
    Apparel
    Consumer Discretionary